{"LabNo":"DR1135",
        "Condons":"1-238","
        SubType":"D",
        "PolymorphismResults":[
        {"Classification":"OTHER","Result":"K14R,L19Q,M36I,R41K,L63Q,I64V,E65D,P4N,K20R,V35I,K49R,V60I,V118VIM,D121Y,K122E,D123E,I135T,G196E,I202V,Q207E,R211K,L228LH"},
        {"Classification":"NRTI","Result":"M41L,E44D,M184V,L210W,T215Y"},
        {"Classification":"NNRTI","Result":"K103N"}
        ],

        "DrugScoreGroups":[
        {"Type":"NNRTI","DrugScores":[{"DrugName":"efavirenz","DrugCode":"EFV","ResistanceLevelText":"High-Level Resistance","DrugNameCode":"efavirenz (EFV)"},{"DrugName":"etravirine","DrugCode":"ETR","ResistanceLevelText":"Susceptible","DrugNameCode":"etravirine (ETR)"},{"DrugName":"nevirapine","DrugCode":"NVP","ResistanceLevelText":"High-Level Resistance","DrugNameCode":"nevirapine (NVP)"},{"DrugName":"rilpivirine","DrugCode":"RPV","ResistanceLevelText":"Susceptible","DrugNameCode":"rilpivirine (RPV)"}]},

        {"Type":"NRTI","DrugScores":[{"DrugName":"abacavir","DrugCode":"ABC","ResistanceLevelText":"High-Level Resistance","DrugNameCode":"abacavir (ABC)"},{"DrugName":"zidovudine","DrugCode":"AZT","ResistanceLevelText":"High-Level Resistance","DrugNameCode":"zidovudine (AZT)"},{"DrugName":"stavudine","DrugCode":"D4T","ResistanceLevelText":"High-Level Resistance","DrugNameCode":"stavudine (D4T)"},{"DrugName":"didanosine","DrugCode":"DDI","ResistanceLevelText":"High-Level Resistance","DrugNameCode":"didanosine (DDI)"},{"DrugName":"emtricitabine","DrugCode":"FTC","ResistanceLevelText":"High-Level Resistance","DrugNameCode":"emtricitabine (FTC)"},{"DrugName":"lamivudine","DrugCode":"3TC","ResistanceLevelText":"High-Level Resistance","DrugNameCode":"lamivudine (3TC)"},{"DrugName":"tenofovir","DrugCode":"TDF","ResistanceLevelText":"Intermediate Resistance","DrugNameCode":"tenofovir (TDF)"}]},{"Type":"PI","DrugScores":[{"DrugName":"atazanavir/r","DrugCode":"ATV/r","ResistanceLevelText":"Susceptible","DrugNameCode":"atazanavir/r (ATV/r)"},{"DrugName":"darunavir/r","DrugCode":"DRV/r","ResistanceLevelText":"Susceptible","DrugNameCode":"darunavir/r (DRV/r)"},{"DrugName":"fosamprenavir/r","DrugCode":"FPV/r","ResistanceLevelText":"Susceptible","DrugNameCode":"fosamprenavir/r (FPV/r)"},{"DrugName":"indinavir/r","DrugCode":"IDV/r","ResistanceLevelText":"Susceptible","DrugNameCode":"indinavir/r (IDV/r)"},{"DrugName":"lopinavir/r","DrugCode":"LPV/r","ResistanceLevelText":"Susceptible","DrugNameCode":"lopinavir/r (LPV/r)"},{"DrugName":"nelfinavir","DrugCode":"NFV","ResistanceLevelText":"Susceptible","DrugNameCode":"nelfinavir (NFV)"},{"DrugName":"saquinavir/r","DrugCode":"SQV/r","ResistanceLevelText":"Susceptible","DrugNameCode":"saquinavir/r (SQV/r)"},{"DrugName":"tipranavir/r","DrugCode":"TPV/r","ResistanceLevelText":"Susceptible","DrugNameCode":"tipranavir/r (TPV/r)"}]}],"ResultComments":[{"Group":"NRTI","Comments":["M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication.","L210W is a TAM that usually occurs in combination with M41L and T215Y. The combination of M41, L210W and T215Y causes high-level resistance to AZT and d4T and intermediate to high-level resistance to ddI, ABC and TDF.","T215Y is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF.","M41L is a TAM that usually occurs with T215Y. In combination, M41L plus T215Y confer intermediate / high-level resistance to AZT and d4T and contribute to reduced ddI, ABC and TDF susceptibility.","E44D is a relatively non-polymorphic accessory mutation and E44A is a nonpolymorphic accessory mutation. Each usually occurs with multiple TAMs."]},{"Group":"NNRTI","Comments":["K103N is a non-polymorphic mutation that causes high-level resistance to NVP and EFV."]},{"Group":"Other","Comments":["V118I is a polymorphic accessory NRTI-resistance mutation that often occurs in combination with multiple TAMs."]}]}